Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
04 Nov 2024
04 Nov 2024
Historique:
received:
06
07
2023
revised:
17
07
2024
accepted:
27
08
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
ppublish
Résumé
Human inborn errors of thymic T cell tolerance underlie the production of autoantibodies (auto-Abs) neutralizing type I IFNs, which predispose to severe viral diseases. We analyze 131 female patients with X-linked dominant incontinentia pigmenti (IP), heterozygous for loss-of-function (LOF) NEMO variants, from 99 kindreds in 10 countries. Forty-seven of these patients (36%) have auto-Abs neutralizing IFN-α and/or IFN-ω, a proportion 23 times higher than that for age-matched female controls. This proportion remains stable from the age of 6 years onward. On imaging, female patients with IP have a small, abnormally structured thymus. Auto-Abs against type I IFNs confer a predisposition to life-threatening viral diseases. By contrast, patients with IP lacking auto-Abs against type I IFNs are at no particular risk of viral disease. These results suggest that IP accelerates thymic involution, thereby underlying the production of auto-Abs neutralizing type I IFNs in at least a third of female patients with IP, predisposing them to life-threatening viral diseases.
Identifiants
pubmed: 39352576
pii: 277003
doi: 10.1084/jem.20231152
pii:
doi:
Substances chimiques
Interferon Type I
0
Autoantibodies
0
I-kappa B Kinase
EC 2.7.11.10
IKBKG protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Institut National de la Santé et de la Recherche Médicale
Organisme : Paris Cité University
Organisme : St. Giles Foundation
Organisme : Rockefeller University
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1TR001866
Pays : United States
Organisme : National Center for Advancing Sciences
Organisme : NIH HHS
ID : R01AI163029
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
Organisme : General Atlantic Foundation
Organisme : Chan-Zuckerberg Biohub
Organisme : French National Research Agency
ID : ANR-10-IAHU-01
Organisme : French Foundation for Medical Research
ID : EQU201903007798
Organisme : European Union's Horizon 2020 research and innovation program
ID : 824110
Organisme : HORIZON-HLTH-2021-DISEASE-04
ID : 101057100
Organisme : Square Foundation
Organisme : Grandir - Fonds de solidarité pour l'enfance
Organisme : SCOR Corporate Foundation for Science
Organisme : French Ministry of Higher Education, Research, and Innovation
Organisme : Japan Society for the Promotion of Science
ID : 22H03041
Organisme : Japan Agency for Medical Research and Development
ID : JP22fk0108514
Organisme : Sidra Medicine
Organisme : Qatar National Research Fund
ID : NPRP9-251-3-045
Organisme : Bettencourt-Schueller Foundation
Organisme : Swedish Research Council
ID : 2021-03118
Organisme : Göran Gustafsson Foundation
ID : 2141
Organisme : Next Generation EU-MUR PNRR
ID : PE00000007
Organisme : University Grenoble Alpes
ID : ANR-17-EURE-0003
Organisme : Association Incontinentia Pigmenti France
Organisme : Filière Santé Maladies Rares Dermatologiques
Organisme : Imagine Institute
Informations de copyright
© 2024 Rosain et al.